Autologous genetically engineered NY-ESO-1 c259 T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.
Mackall C, D'Angelo S, Grupp S, Odunsi K, Cristea M, Linette G, Kluger H, Kari G, Pandite L, Holdich T, Norry E, Binder-Scholl G, Amado R. Autologous genetically engineered NY-ESO-1 c259 T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors. Journal Of Clinical Oncology 2016, 34: tps3101-tps3101. DOI: 10.1200/jco.2016.34.15_suppl.tps3101.Peer-Reviewed Original Research